Study Objective Despite evidence that supports the use of sacubitril/valsartan–the first
angiotensin II receptor blocker–neprilysin inhibitor–for mortality reduction in patients with …

Background: US guidelines recommend that patients with heart failure with reduced ejection
fraction (HFrEF), who tolerate an ACEI (angiotensin-converting enzyme inhibitor) or ARB …

Aims To assess the proportion of patients with heart failure and reduced ejection fraction
(HFrEF) who are eligible for sacubitril/valsartan (LCZ696) based on the European Medicines …

This review aims to elucidate the optimal dosing of angiotensin receptor-neprilysin inhibitor
(ARNI) therapy in the heart failure (HF) treatment paradigm through examination of the trial …

Background Sacubitril/valsartan is an effective treatment for heart failure with reduced
ejection fraction (HFrEF) based on clinical trial data. However, little is known about its use or …

Background Guidelines recommend targeting systolic blood pressure (SBP)< 130 mm Hg in
heart failure with preserved ejection fraction (HFpEF) with limited data. Objectives This study …

Aims Elevated left ventricular filling pressure (LVFP) is a powerful indicator of worsening
clinical outcomes in heart failure with preserved ejection fraction (HFpEF); however …

Abstract Aims The PARAGLIDE-HF trial demonstrated reductions in natriuretic peptides with
sacubitril/valsartan compared with valsartan in patients with heart failure (HF) with mildly …

Objectives: This study assessed whether the benefit of sacubtril/valsartan therapy varied
with clinical stability. Background: Despite the benefit of sacubitril/valsartan therapy shown …

Background Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg)
doses of sacubitril/valsartan. Objectives The purpose of this study was to investigate the …